Luis Diaz,Bert Vogelstein,Kenneth W. Kinzler,Nickolas Papadopoulos,Dung Le
申请号：
US15611017
公开号：
US20170267760A1
申请日:
2017.06.01
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.
